美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Alcobra Ltd.

10.22

0.0000

成交量：- -

成交額：- -

市值：2.82億

市盈率：-11.48

高：10.22

開：10.22

低：10.22

收：10.22

52周最高：18.04

52周最低：5.81

股本：2,756.30萬

流通股本：888.10萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.8900

淨資產收益率：--

總資產收益率：--

市淨率：5.96

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Alcobra Ltd.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.alcobra-pharma.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Alcobra Ltd.在以色列註冊，並於2008年2月7日開始運營。該公司是一家新興生物製藥公司，主要致力於治療神經干擾的專利藥物開發與商業化，比如注意力缺陷多動症。公司正對藥物MG01C1進行更多的臨床試驗，如果試驗成功將向美國食品藥品管理局和其他國家的監管機構申請銷售。公司還沒有通過銷售產品取得收入，也不預期產生巨大收入，除非MG01C1獲得銷售許可並且商業化。因此，公司尚處於發展階段，正如ASC所定義的“發展階段實體”。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ADHD/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ADHD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","market":"US","secType":"STK","nameCN":"Alcobra Ltd.","latestPrice":10.22,"timestamp":1510952400000,"preClose":10.22,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":8881019,"shares":27563000,"eps":-0.89,"marketStatus":"退市","change":0,"latestTime":"03-10 11:42:29 EDT","open":10.22,"high":10.22,"low":10.22,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.89,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1773172800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.22,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","floatShares":8881019,"roa":"--","roe":"--","lyrEps":0,"shares":27563000,"dividePrice":0,"high":10.22,"amplitude":0,"preClose":10.22,"low":10.22,"week52Low":5.8113,"pbRate":"5.96","week52High":18.0414,"institutionHeld":0,"latestPrice":10.22,"eps":-0.89,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.89,"open":10.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADHD\",params:#limit:5,,,undefined,":[{"date":"2017-11-16","symbol":"ADHD","newSymbol":"ARCT","type":"symbolChange","dateTimestamp":1510808400000},{"date":"2017-11-15","symbol":"ADHD","type":"split","dateTimestamp":1510722000000,"forFactor":7,"toFactor":1},{"market":"US","date":"2017-11-09","symbol":"ADHD","fiscalQuarterEnding":"2017/09","expectedEps":-0.08,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2017-08-11","symbol":"ADHD","fiscalQuarterEnding":"2017/06","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1502424000000,"reportTimeType":"","actualEps":-0.13},{"market":"US","date":"2017-05-30","symbol":"ADHD","fiscalQuarterEnding":"2017/03","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1496116800000,"reportTimeType":"","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADHD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADHD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.alcobra-pharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Alcobra Ltd.在以色列註冊，並於2008年2月7日開始運營。該公司是一家新興生物製藥公司，主要致力於治療神經干擾的專利藥物開發與商業化，比如注意力缺陷多動症。公司正對藥物MG01C1進行更多的臨床試驗，如果試驗成功將向美國食品藥品管理局和其他國家的監管機構申請銷售。公司還沒有通過銷售產品取得收入，也不預期產生巨大收入，除非MG01C1獲得銷售許可並且商業化。因此，公司尚處於發展階段，正如ASC所定義的“發展階段實體”。","exchange":"NASDAQ","name":"Alcobra Ltd.","nameEN":"Alcobra"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ADHD\",market:\"US\",,,undefined,":null}}